CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Inc. COP Y/Y Annual
Cardiff Lexington Corporation  (CDIF)
Other Ticker:  
 
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

CDIF's Income from Cont. Operations Growth by Quarter and Year

Cardiff Lexington's Income from Cont. Operations results by quarter and year




CDIF Income from Cont. Operations (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December -0.91 0.42 -4.33 6.14
III Quarter September -1.98 1.98 -0.63 -1.79
II Quarter June -0.13 0.82 -0.04 -3.01
I Quarter March -0.17 -0.02 -0.47 -1.57
FY   -3.19 3.20 -5.47 -0.23



CDIF Income from Cont. Operations fourth quarter 2024 Y/Y Growth Comment
Cardiff Lexington Corporation in the fourth quarter 2024 recorded loss from continued operations of $ -0.91 millions.

Looking into fourth quarter 2024 results within Healthcare Facilities industry 10 other companies have achieved higher Income from Cont. Operations growth. While Cardiff Lexington Corporation' s Income from Cont. Operations no change of % ranks overall at the positon no. 1157 in the fourth quarter 2024.


CDIF Income from Cont. Operations ( Y/Y Growth %) 2024
 2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Cardiff Lexington's fourth quarter 2024 Income from Cont. Operations $ -0.91 millions CDIF's Income Statement
Cardiff Lexington's fourth quarter 2023 Income from Cont. Operations $ 0.42 millions Quarterly CDIF's Income Statement


CDIF Income from Cont. Operations (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
IV Quarter December - -78.79 % - -
III Quarter September - 141.46 % - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -


Current CDIF Income Statement >> Back to CDIF Growth rate Comparisons >>


Income from Cont. Operations fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #11
Healthcare Sector #83
Overall #1157

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
183.78 % -1438.09 % -7601.25 %
(Mar 31 2022)   (Sep 30 2021)
Income from Cont. Operations fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #11
Healthcare Sector #83
Overall #1157
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
183.78 % -1438.09 % -7601.25 %
(Mar 31 2022)   (Sep 30 2021)

Income from Cont. Operations by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Cardiff Lexington's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CDIF's IV. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Cardiff Lexington Corporation in the IV. Quarter 2024 showed loss from continued operations of $ -0.91 millions, some analyst said, that current results are slight up side relative to the -1.98 millions in the third quarter.

Within Healthcare Facilities industry Cardiff Lexington Corporation achieved highest sequential Income from Cont. Operations growth. While Cardiff Lexington's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CDIF's IV. Quarter Q/Q Income from Cont. Operations Comment
Even if Cardiff Lexington Corporation in the IV. Quarter 2024 showed loss from continued operations of $ -0.91 millions, it should be said, that those numbers show recovery in contrast to the -1.98 millions in the third quarter.

Within Healthcare Facilities industry Cardiff Lexington Corporation achieved highest sequential Income from Cont. Operations growth. While Cardiff Lexington's Income from Cont. Operations growth quarter on quarter, overall rank is .


Cardiff Lexington's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)
Cumulative Income from Cont. Operations 12 Months Ending $ -3.19 $ -1.86 $ 2.10 $ 3.05 $ 3.20
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - -31.12 % -4.87 % -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 1157 # 967 # 1038 # 795 # 0


Cumulative Income from Cont. Operations growth Comment
Cardiff Lexington Corporation realized trailing twelve months loss from continued operations of $ -3 millions, in the Dec 31 2024, compare to Income from Cont. Operations of $ 3 millions a year ago.

Cardiff Lexington Corporation achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
183.78 %
-1438.09 %
-7601.25 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 83
S&P 500 # 1157
Cumulative Income from Cont. Operations growth Comment
Cardiff Lexington Corporation realized trailing twelve months loss from continued operations of $ -3 millions, in the Dec 31 2024, compare to Income from Cont. Operations of $ 3 millions a year ago.

Cardiff Lexington Corporation achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
183.78 %
-1438.09 %
-7601.25 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 83
S&P 500 # 1157




Other Income from Cont. Operations Growth
Healthcare Facilities Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
CDIF's Income from Cont. Operations Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for CDIF's Competitors
Income from Cont. Operations Growth for Cardiff Lexington's Suppliers
Income from Cont. Operations Growth for CDIF's Customers

You may also want to know
CDIF's Annual Growth Rates CDIF's Profitability Ratios CDIF's Asset Turnover Ratio CDIF's Dividend Growth
CDIF's Roe CDIF's Valuation Ratios CDIF's Financial Strength Ratios CDIF's Dividend Payout Ratio
CDIF's Roa CDIF's Inventory Turnover Ratio CDIF's Growth Rates CDIF's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2024
Integra Lifesciences Holdings Corp-2.02%$ -2.017 millions
Corcept Therapeutics Inc-2.41%$ -2.413 millions
Insulet Corporation-2.52%$ -2.517 millions
Profound Medical Corp -2.64%$ -2.636 millions
Perspective Therapeutics Inc -3.39%$ -3.390 millions
West Pharmaceutical Services Inc -5.04%$ -5.036 millions
Vertex Pharmaceuticals Inc-5.76%$ -5.760 millions
Iqvia Holdings Inc -6.82%$ -6.823 millions
Inmode Ltd -8.41%$ -8.410 millions
Earth Science Tech Inc -8.44%$ -8.442 millions
Hca Healthcare Inc -9.40%$ -9.404 millions
Johnson and Johnson-12.94%$ -12.941 millions
Edwards Lifesciences Corporation-14.39%$ -14.390 millions
Align Technology inc -16.29%$ -16.294 millions
Amgen Inc -18.25%$ -18.253 millions
Hologic Inc-18.46%$ -18.458 millions
Alpha Pro Tech Ltd -19.17%$ -19.169 millions
Regeneron Pharmaceuticals Inc -20.86%$ -20.861 millions
Progyny Inc -21.81%$ -21.811 millions
National Research Corporation-25.93%$ -25.931 millions
Amphastar Pharmaceuticals Inc -26.20%$ -26.201 millions
Neurocrine Biosciences Inc -30.20%$ -30.196 millions
Icu Medical Inc-31.02%$ -31.018 millions
Dariohealth Corp -32.57%$ -32.573 millions
Siga Technologies Inc-36.67%$ -36.669 millions
Exagen Inc -37.28%$ -37.278 millions
Penumbra Inc -37.87%$ -37.875 millions
Dexcom Inc -40.81%$ -40.812 millions
Chemomab Therapeutics Ltd -42.43%$ -42.426 millions
Zimmer Biomet Holdings Inc -42.79%$ -42.792 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com